Drawing for MULTIBODY

USPTO serial 79209028

MULTIBODY

Reviewed by CopyMark Law Group

Reg. 5450600Status 709
Filing date
Status date
Registration date
Apr 24, 2018
Examiner
JACKSON, STEVEN W
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MULTIBODY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christopher J. Schulte

Christopher J. Schulte Merchant & Gould P.C.P.O. Box 2910Minneapolis, MN 55402-0910UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Chemicals used in industry and science; chemicals for laboratory research purposes; monoclonal antibodies and antibody fragments for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes; monoclonal antibody reagents for scientific and laboratory use; monoclonal antibodies and antibody fragments for scientific research purposes for use in the manufacture of therapeutic productsSECTION 71 - CANCELLED—
005Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; monoclonal antibodies for therapeutic purposes, namely, therapeutic agents for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the discovery, preclinical and clinical development of therapeutic products; antibodies and antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for use in the manufacture of therapeutic productsSECTION 71 - CANCELLED—
040Treatment and transformation of materials, namely, custom manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing in the field of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragmentsSECTION 71 - CANCELLED—
042Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; research and development in the field of antibodies and antibody fragments; medical research laboratory services relating to antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific research relating to the discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment designSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 22, 2026INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Dec 30, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Dec 30, 2025INPCINVALIDATION PROCESSED—
Jul 8, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jun 3, 2025LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Nov 8, 2024C71TCANCELLED SECTION 71—
Nov 8, 2024RHRDRESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED—
Oct 27, 2023LIMNLIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED—
Aug 19, 2023RHRDRESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED—
Apr 24, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Sep 7, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Aug 9, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Aug 9, 2018FIMPFINAL DISPOSITION PROCESSED—
Jul 24, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Apr 24, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 6, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 1, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 17, 2018NPUBNOTICE OF PUBLICATION—
Dec 28, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 21, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 21, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 19, 2017ALIEASSIGNED TO LIE—
Dec 12, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 7, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 14, 2017RFNTREFUSAL PROCESSED BY IB—
Jun 23, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jun 22, 2017RFRRREFUSAL PROCESSED BY MPU—
Jun 14, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jun 13, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 9, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 6, 2017DOCKASSIGNED TO EXAMINER—
Jun 5, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 1, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance